
X
FDA begins review of Samsung Bioepis/Biogen’s Lucentis biosimilar
https://pharmaphorum.com/news/novartis-lucentis-could-face-biosimilar-competition/
Companies signed risk-sharing deal last year
But deal with Samsung prevents US launch until mid-2023
Mylan and Biocon resolve biosimilar manufacturing issues
No-one can launch biosimilars until patent expires next year
South Korean firm looking to develop novel drugs